Loading
A phase 3 trial of FPI-2265, Cabazitaxel, Abiraterone acetate in prostate cancer, run by AstraZeneca, now recruiting.
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) is a phase 3 interventional study registered as NCT07611110 by AstraZeneca, with 670 participants planned, started 2026-05-04 and due to reach its primary completion in 2029-06-04. Interventions recorded: Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Darolutamide, Apalutamide, Abiraterone acetate, Enzalutamide.
Shares FPI-2265, Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares FPI-2265, Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares Apalutamide, Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Cabazitaxel, Abiraterone acetate, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Darolutamide, Apalutamide, Abiraterone acetate, Enzalutamide.
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/